The Quantellect read.As of Nov 19, 2026, 4 active firms cover Bioventus Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $14.00 to $19.00, so the covering firms are broadly aligned. The average target of $16.00 sits 51% above the current $10.63. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.15 next quarter toward $0.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$16.00
+50.5% upside
Average target across 4 active firms as of Nov 19, 2026 vs $10.63 current
Highest Target$19.00
Average Target$16.00
Lowest Target$14.00
Detailed analyst forecasts for BVS
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate BVS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BVS EPS & revenue forecast
EPS · NEXT QUARTER
$0.15
Range $0.13 – $0.18 · 4 analysts · +0% YoY
Next period, 4 analysts expect Bioventus Inc to earn $0.15 a share (range $0.13 – $0.18), versus $0.15 a year earlier. Full-year consensus is $0.77, growing to $0.89 the year after.
REVENUE · NEXT QUARTER
$139.4M
Range $138.3M – $140.6M · 4 analysts · +6% YoY
Revenue is expected to reach $139.4M (range $138.3M – $140.6M), +5.5% year-over-year. Full-year consensus is $594.9M, rising to $633.1M next year.
Top analysts covering Bioventus Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BVS.
#1
Sarah James
Cantor Fitzgerald · Rank #159
Buy
$15.00+41.1% to target
Overall win rate
37%
+ Follow
#2
Ross Osborn
Cantor Fitzgerald · Rank #238
Buy
$14.00+31.7% to target
Overall win rate
34%
+ Follow
#3
CC
Caitlin Cronin
Canaccord Genuity · Rank #260
Buy
$19.00+78.7% to target
Overall win rate
39%
+ Follow
#4
Michael Petusky
Barrington Research · Rank #452
Buy
$14.00+31.7% to target
Overall win rate
32%
+ Follow
#5
LS
Lawrence Solow
CJS Securities
Buy
$14.00+31.7% to target
Coverage
—
+ Follow
BVS stock forecast FAQ
What is BVS's average 12-month price target?+
The 4 active firms with a live target average $16.00 for Bioventus Inc over the next 12 months, ranging from a $19.00 high to a $14.00 low, as of Nov 19, 2026.
Is BVS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BVS?+
The Street-high target is $19.00 (Canaccord Genuity), and the Street-low is $14.00 (Barrington Research). The average of all 4 active-firm targets is $16.00.
How many active Wall Street firms cover BVS?+
4 active firms have a recognized rating on Bioventus Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BVS?+
Among analysts who currently cover BVS, Sarah James of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #159). Their current call is Buy with a $15.00 target.
What is Bioventus Inc's projected EPS for next quarter?+
The consensus estimate is $0.15 per share (range $0.13 – $0.18) across 4 analysts. Full-year EPS is projected at $0.77, rising to $0.89 the following year.
How much revenue is Bioventus Inc expected to report next quarter?+
Consensus revenue is $139.4M (range $138.3M – $140.6M). Full-year revenue is projected at $594.9M, growing to $633.1M next year.
Have analysts been upgrading or downgrading BVS lately?+
As of Nov 19, 2026, 4 of 4 active firms rate BVS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BVS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.